A Novel Risk Prediction Model for Post-treatment Ischemic Stroke Recurrence Using Plasma Antithrombin III and Thromboelastography
ATIII and TEG Integrated Model for Predicting Ischemic Stroke Recurrence Post-DAPT
Abstract
Objective: The primary aim of this investigation was to build and test a novel risk prediction model incorporating plasma antithrombin III (ATIII) activity and thrombelastography (TEG)-derived parameters. This approach seeks to enhance the ability to stratify the risk of stroke recurrence among ischemic stroke (IS) patients receiving dual antiplatelet therapy (DAPT).
Methods: In this prospective cohort study, 200 consecutive patients diagnosed with non-cardiogenic IS were recruited during a one-year period (May 2024 to May 2025). All participants had their ATIII activity, TEG parameters, and coagulation function indicators tested within 24-72 hours of DAPT commencement. After initial variable screening via univariate analysis. A logistic regression-based risk model was built, with its ability to distinguish outcomes evaluated using the receiver operating characteristic (ROC) curve.
Results: Recurrent events occurred in 21.00% (42/200) of cases within 3 months post-DAPT. Multivariate analysis established ATIII, TEG-LY30, and D-Dimer as independent risk factors and TEG-MA as protective. The resultant model exhibited superior predictive power (AUC=0.9480, 95%CI=0.9148~0.9813; sensitivity 90.48%, specificity 86.71%). Internal validation, yielding AUCs of 0.9521 in the training set and 0.9437 in the validation set, verified the model's strong generalizability. Subgroup evaluations further revealed the model’s robust performance in both large artery atherosclerosis (AUC=0.9505) and small vessel occlusion (AUC=0.9395) subtypes.
Conclusion: Integrating ATIII activity with TEG parameters enables the development of a novel model to predict the risk of IS relapse following DAPT.
Copyright (c) 2025 Yi Cheng, Baobao Huang, Shan Jiang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.